image description  

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B

  • 2011/01/01
Type de publication
  • Articles
  • Chappuis F
  • Alirol E
  • Worku DT
  • Mueller Y
  • Ritmeijer K
  • Maladies négligées

Visceral leishmaniasis (kala azar), a fatal disease if left untreated, is one of the most neglected tropical diseases. Poor and remote areas of South Asia and East Africa are the most affected.

Pentavalent antimonial (SbV) drugs have been the mainstay of visceral leishmaniasis (VL) therapy in East Africa for the past 70 years. These drugs are administered parenterally for 30 days. Their potential for toxicity is high among VL patients, and drug-induced renal failure, acute pancreatitis, or cardiotoxicity can result in death.